정밀 심장병학 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제공, 샘플 유형, 기술, 용도, 최종사용자, 지역별 및 경쟁(2021-2031년)

The Global Precision Cardiology Market is anticipated to expand from USD 19.88 Billion in 2025 to USD 39.64 Billion by 2031, reflecting a compound annual growth rate of 12.19%. This sector is characterized by the strategic utilization of genomic profiling, biomarker analysis, and phenotype data to customize cardiovascular prevention and treatment plans according to an individual's unique biological makeup. The market's trajectory is largely driven by the rising global prevalence of cardiovascular conditions and the ongoing evolution of next-generation sequencing technologies, which facilitate earlier and more precise disease detection. According to the World Heart Federation, cardiovascular diseases caused 20.5 million deaths worldwide in 2024, a figure that emphasizes the urgent need for personalized medical interventions to enhance therapeutic outcomes.

However, the market faces significant hurdles due to the high costs associated with genetic testing and insufficient reimbursement structures. The substantial financial requirements for comprehensive genomic assays, exacerbated by complex and inconsistent insurance policies, limit access for both healthcare systems and patients. Consequently, these economic constraints effectively restrict the widespread clinical adoption of precision diagnostic tools, acting as a major impediment to the overall growth of the sector.

Market Driver

The incorporation of Artificial Intelligence and Machine Learning into diagnostics serves as a primary catalyst for the Global Precision Cardiology Market, fundamentally transforming how cardiovascular conditions are identified and managed. AI algorithms are increasingly utilized to process intricate datasets, ranging from genomic profiles to cardiac imaging, allowing clinicians to predict disease progression with unprecedented accuracy. This technological progress is validated by the regulatory landscape; according to Cardiovascular Business in January 2025, cardiology has emerged as a leader in medical innovation with 161 FDA-cleared AI algorithms available for clinical application. These tools not only streamline diagnostic workflows but also enable better patient stratification for targeted therapies, addressing the demand for personalized care and boosting market adoption.

Simultaneously, rising investments in Precision Medicine Research and Development are propelling sector expansion by supplying the capital needed to turn genomic discoveries into commercially viable therapeutics. Venture capital firms and institutional investors are heavily funding biotechnology companies focused on gene therapies and molecular diagnostics, helping to offset the steep costs associated with clinical trials. For example, MedPath reported in May 2025 that Lexeo Therapeutics secured $80 million to advance its pipeline of genetic medicines for cardiovascular diseases. Furthermore, commercial viability is being strengthened by improved reimbursement structures; as noted by BioSpace in December 2025, the Centers for Medicare and Medicaid Services (CMS) finalized a payment rate of $854 for precision cardiovascular tests, significantly enhancing market access and incentivizing further innovation.

Market Challenge

The prohibitive cost of genetic testing, combined with inadequate reimbursement frameworks, represents a primary economic barrier stifling the expansion of the Global Precision Cardiology Market. While advanced genomic profiling and next-generation sequencing demand significant upfront capital, insurance coverage for these diagnostics remains inconsistent and often confined to narrow clinical criteria. As a result, healthcare providers are reluctant to adopt these expensive tools routinely, as the financial burden frequently shifts to hospitals or patients. This lack of clear payment pathways prevents the transition of precision diagnostics from niche research applications into standard clinical care, directly limiting the addressable market size for diagnostic companies.

The reluctance of payers to authorize coverage is largely driven by the immense financial pressure that cardiovascular conditions already impose on health systems, necessitating rigorous cost containment. According to the European Society of Cardiology, cardiovascular disease cost the EU economy approximately €282 billion in 2024. Given these substantial existing expenses, budgetary limitations force payers to strictly evaluate the cost-effectiveness of new genetic assays. Until economic data clearly demonstrates clinical benefits to justify comprehensive coverage, high costs will continue to cap market penetration and revenue potential for precision cardiology innovators.

Market Trends

The expansion of Polygenic Risk Scores in clinical practice is fundamentally changing cardiovascular risk stratification by moving focus from rare monogenic variants to the cumulative effect of common genetic variations. Unlike traditional risk models that depend on established physiological markers, these scores aggregate millions of low-impact genetic variants to identify susceptibility in broader patient populations before clinical symptoms appear. This approach enables earlier, targeted preventative interventions for individuals who might otherwise be classified as low-risk by conventional standards. Recent data supports the utility of this method; according to the European Heart Journal in September 2024, integrating polygenic risk scores with standard clinical assessments resulted in a 47.7% relative increase in identifying high-risk individuals aged 40 to 54, significantly enhancing early detection capabilities.

At the same time, the incorporation of Wearable Digital Biomarkers into patient care is transforming diagnostic precision by facilitating continuous, longitudinal monitoring of physiological parameters outside the clinical setting. By leveraging consumer-grade devices capable of capturing real-time photoplethysmography and electrocardiogram data, clinicians can now detect transient arrhythmias and sporadic cardiac events that episodic in-clinic testing frequently misses. This constant stream of digital biomarkers supports a dynamic understanding of patient health, allowing for rapid adjustments in management strategies based on real-world evidence. The efficacy of this trend is highlighted by clinical findings; the Journal of the American College of Cardiology reported in September 2024 that the use of continuous wearable heart monitors led to a 52% increase in atrial fibrillation diagnoses compared to standard care, underscoring the value of remote digital sensing.

Key Market Players

• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic Plc
• GE HealthCare Technologies Inc.
• Edwards Lifesciences Corporation
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Bayer AG
• Quest Diagnostics Incorporated
• PerkinElmer Genomics

Report Scope

In this report, the Global Precision Cardiology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Cardiology Market, By Offering

• Products v/s Service

Precision Cardiology Market, By Sample Type

• Blood v/s Non-Blood

Precision Cardiology Market, By Technology

• Sequencing
• Polymerase Chain Reaction
• Microarray
• Others

Precision Cardiology Market, By Application

• Cardiomyopathy
• Arrhythmia
• Aortopathy and Vascular Diseases
• Others

Precision Cardiology Market, By End User

• Hospitals & Clinics
• Academic & Research Institutions
• Others

Precision Cardiology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Precision Cardiology Market.

Available Customizations:

Global Precision Cardiology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Precision Cardiology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Offering (Products v/s Service)
  • 5.2.2. By Sample Type (Blood v/s Non-Blood)
  • 5.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Others)
  • 5.2.4. By Application (Cardiomyopathy, Arrhythmia, Aortopathy and Vascular Diseases, Others)
  • 5.2.5. By End User (Hospitals & Clinics, Academic & Research Institutions, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Precision Cardiology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Offering
  • 6.2.2. By Sample Type
  • 6.2.3. By Technology
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Precision Cardiology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Offering
      • 6.3.1.2.2. By Sample Type
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Precision Cardiology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Offering
      • 6.3.2.2.2. By Sample Type
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Precision Cardiology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Offering
      • 6.3.3.2.2. By Sample Type
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Precision Cardiology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Offering
  • 7.2.2. By Sample Type
  • 7.2.3. By Technology
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Precision Cardiology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Offering
      • 7.3.1.2.2. By Sample Type
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. France Precision Cardiology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Offering
      • 7.3.2.2.2. By Sample Type
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Precision Cardiology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Offering
      • 7.3.3.2.2. By Sample Type
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Precision Cardiology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Offering
      • 7.3.4.2.2. By Sample Type
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Precision Cardiology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Offering
      • 7.3.5.2.2. By Sample Type
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia Pacific Precision Cardiology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Offering
  • 8.2.2. By Sample Type
  • 8.2.3. By Technology
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Precision Cardiology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Offering
      • 8.3.1.2.2. By Sample Type
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Precision Cardiology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Offering
      • 8.3.2.2.2. By Sample Type
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Precision Cardiology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Offering
      • 8.3.3.2.2. By Sample Type
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Precision Cardiology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Offering
      • 8.3.4.2.2. By Sample Type
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Precision Cardiology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Offering
      • 8.3.5.2.2. By Sample Type
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. Middle East & Africa Precision Cardiology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Offering
  • 9.2.2. By Sample Type
  • 9.2.3. By Technology
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Precision Cardiology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Offering
      • 9.3.1.2.2. By Sample Type
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Precision Cardiology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Offering
      • 9.3.2.2.2. By Sample Type
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Precision Cardiology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Offering
      • 9.3.3.2.2. By Sample Type
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. South America Precision Cardiology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Offering
  • 10.2.2. By Sample Type
  • 10.2.3. By Technology
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Precision Cardiology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Offering
      • 10.3.1.2.2. By Sample Type
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Precision Cardiology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Offering
      • 10.3.2.2.2. By Sample Type
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Precision Cardiology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Offering
      • 10.3.3.2.2. By Sample Type
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Precision Cardiology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Boston Scientific Corporation
• 15.3. Medtronic Plc
• 15.4. GE HealthCare Technologies Inc.
• 15.5. Edwards Lifesciences Corporation
• 15.6. Illumina, Inc.
• 15.7. Thermo Fisher Scientific Inc.
• 15.8. Bayer AG
• 15.9. Quest Diagnostics Incorporated
• 15.10. PerkinElmer Genomics

16. Strategic Recommendations

17. About Us & Disclaimer